Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 9/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261097 | 0.72 | GABRA1 (0.44) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL12469686 | 0.69 | GABRA1 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL13666788 | 0.66 | GABRA1 (0.35) | GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2042948 | 0.66 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL4485534 | 0.63 | IDO1 (0.36) | GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL16566670 | 0.62 | CA2 (0.32) | — | |
| SCHEMBL4441393 | 0.62 | CA2 (0.37) | — | |
| SCHEMBL22612495 | 0.61 | GABRA1 (0.35) | GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL5261894 | 0.61 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2331355 | 0.59 | TRPV4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440969-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-09-13 | — | — | US | claimed |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2015-03-19 | — | — | US | claimed |
| EP-2516438-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | claimed |
| WO-2011079133-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-06-30 | — | — | WO | claimed |
| US-9440969-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2015-03-19 | — | — | US | disclosed |
| EP-2516438-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2011079133-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | GABRA1 464/4885GABRG2 438/4885GABRB3 977/4885 |
| US-20150080372-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | GABRA1 464/4885GABRG2 438/4885GABRB3 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.